Slide 1: Pfizer Oncology Analyst Call
Pfizer Oncology Analyst Call June 9, 2017 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our discussions during this conference call will include forward-looking statements about, among other things, our oncology strategy, our in-line and pipeline oncology portfolio, including but not limited to IBRANCE, BOSULIF, INLYTA, XTANDI, XALKORI, BAVENCIO, SUTENT, MYLO
Slide 3: Liz Barrett, Global President and General Manager, Pfizer Oncology
Liz Barrett Global President and General Manager, Pfizer Oncology 3
Slide 4: Pfizer Oncology: Redefining Life with Cancer
Pfizer Oncology: Redefining Life with Cancer 9 Potential for 18 triplets in Oncology assets Approved Oncology medicines 6 clinic by 2018 in clinical development 5 580K+ 11 Patients treated IO Designations with approved compounds in since 2013 therapies since 2006 clinic in 2017 6 Oncology assets in
Slide 5: Focused to Achieve Our Goals
Focused to Achieve Our Goals To be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer Key Focus Areas IBRANCE & Immuno- Patients XTANDI* Oncology First • Partner with and • Avelumab: • Real-world support key backbone PD-L1 Evidence P
Slide 6: Oncology: Where We Are Today, and the Future
Pfizer Oncology: Where We Are Today, and the Future: Growing in-line portfolio and robust pipeline TODAY FUTURE Growing Product Line Growing Late-Stage Portfolio Diversified Early Pipeline Palbociclib Immuno-Oncology Breast Cancer • Avelumab (PD-L1) Avelumab (PD-L1) • 4-1BB (CD137) 9 Registrational
Slide 7: 2017 ASCO Abstracts Continue to Underscore Breadth Across Tumor Types
2017 ASCO Abstracts Continue to Underscore Breadth Across Tumor Types… >50 Abstracts presented on Pfizer compounds Nine Pfizer-Sponsored Oral Presentations: • In-Line Products: • IBRANCE – Overall survival data from Phase 2b PALOMA-1 • BOSULIF – Phase 3 vs imatinib in newly-Dx’d CML patients • SUTEN
Slide 8: Key ASCO Data: Overall Survival Results from Phase 2b PALOMA-1 Trial
Key ASCO Data: Overall Survival Results from Phase 2 PALOMA-1 Trial in 1L ER+/HER2- Metastatic Breast Cancer As reported initially, with longer follow-up, patients receiving palbociclib in PALOMA-1 had a numerically longer survival time than those receiving letrozole alone. This difference did not r
Slide 9: Robust IBRANCE Clinical Development Program
Robust IBRANCE Clinical Development Program Beyond BC PALLAS PENELOPE PATINA (Readout Dates of Key Trials) PEARL Pancreas, Early Breast H&N, etc. PALOMA-2 Indication Ladder Early Breast (Stage II/III) 1L HER2+ (High Risk) PALOMA-3 Recurrent Advanced HER2- Breast 2020+ PALOMA-1 Advanced 2020 1L HER2-
Slide 10: Talazoparib: An Investigational PARP Inhibitor
Talazoparib: An Investigational PARP Inhibitor • Talazoparib is an oral PARP inhibitor • In preclinical studies, talazoparib appears to have dual mechanisms of action1 • Catalytic inhibition (left image): may prevent PARP-mediated DNA damage repair • Trapping of PARP–DNA complexes (right image): may
Slide 11: Key ASCO Data: Final Results from Phase 2 ABRAZO Trial
Key ASCO Data: Final Results from Phase 2 ABRAZO Trial • Study of Talazoparib in 2 cohorts: following platinum –based therapy or following multiple cytotoxic regimens but not platinum in advanced breast cancer patients with germline 7.4 (95% CI: 1.9–NR); n=6 BRCA1/2 mutations • Talazoparib exhibited
Slide 12: Pfizer in Lung Cancer
Pfizer in Lung Cancer Non-Small Cell Lung Cancer (NSCLC) Non-Squamous (~70%) EGFR ROS1 C-MET KRAS Squamous (~30%) (12-35%) ALK BRAF Other WT Significant (1- exon14 (15- (3-5%) 2-3% mutations (30-60%) regional variation 2%) (3-4%) 25%) Actionable mutations targeted Biomarker negative/ no actionable m
Slide 13: Key ASCO Data: ARCHER 1050 Study Design
Key ASCO Data: ARCHER 1050 Study Design Phase 3 randomized open-label study to evaluate dacomitinib as first-line treatment for patients with advanced NSCLC with an EGFR-activating mutation Primary endpoint PFS by blinded independent ● Advanced NSCLC with EGFR- Dacomitinib review (IR) activating mut
Slide 14: Confirmed Response Rates for Lorlatinib in ALK+ Patients
Confirmed Response Rates for Lorlatinib in ALK+ Patients Previously Treated With ≥1 ALK TKI Total EXP2 EXP3 EXP4 EXP5 (EXP2–5) a Prior CRZ 1 Prior TKI 2 Prior TKIs 3 Prior TKIs (n=82) (n=7) (n=18) (n=44)b (n=13) Best overall response, n (%)c Complete response 1 (1.2) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Slide 15: Key ASCO Data: Avelumab in 1L MCC
Key ASCO Data: Avelumab in 1L MCC 15
Slide 16: Tailored Approaches to Drive Strong and Diverse Pipeline
Tailored Approaches to Drive Strong and Diverse Pipeline “COLD TUMORS” “WARM TUMORS” “HOT TUMORS” ER + Breast, Breast, Lung, Lung, Melanoma, Liver, Prostate, Leukemia Ovarian, Brain, Kidney Bladder, Head & Neck P-cadherin IDO1 PD-1 / PD-L1 Next-Gen mAB Small Molecule CTLA4 Bi-specifics mAb UCART19 C
Slide 17: Immuno-Oncology Development Approaches
Pfizer Immuno-Oncology Development Approaches 1. Eliciting Immunogenic Cell Death 2. Combining Anti- 3. Sustaining Immune Angiogenic Approaches Responses with Immunotherapy 4. Inhibiting an Immune 5. Combining with DNA Suppressive Damage Response Microenvironment Medicines 17
Slide 18: Immuno-Oncology Development Approaches
Pfizer Immuno-Oncology Development Approaches 1 Avelumab + CDDP/taxane ovarian 1L* CELL DEATH Avelumab + PLD ovarian R/R* Avelumab + CDDP/RT LA HNSCC* CDDP/gem seq with avelumab UCC 1L* Avelumab + lorlatinib ALK+ NSCLC Avelumab + XALKORI NSCLC Avelumab + bend+ ritux DLBCL 2 3 AA COMBOS SUSTAIN Avelu
Slide 19: Avelumab Registrational Program
Avelumab Registrational Program Tumor Phase 2 Phase 3 chemotherapy/avelumab (1L; switch/maintenance) GASTRIC avelumab (3L) HEAD & NECK avelumab/RT/CDDP (LA) MCC BAVENCIO Approved avelumab(2L) NSCLC avelumab (1L) avelumab/chemotherapy (UPFRONT) OVARIAN avelumab/doxil (PLAT RES/REF) RCC avelumab/INLYT
Slide 20: Key ASCO Data: JAVELIN Renal 100 Results
Key ASCO Data: JAVELIN Renal 100 Results Percent change from baseline in sum of target lesion diameters* (n=53 †) 45 patients experienced tumor shrinkage 32 patients had a confirmed objective response • Confirmed ORR was 58.2% (95% CI, 44.1–71.3) • An additional patient with ongoing therapy had an u
Slide 21: Pfizer Continues to Break Boundaries with a Growing Pipeline of Cancer Therapies
Pfizer Continues to Break Boundaries with a Growing Pipeline of Cancer Therapies In Summary… • Our extensive pipeline has ushered many firsts in cancer care and includes therapies for a range of diseases such as kidney, breast, lung and blood cancers. • Further, we are excited about the future and p
Slide 22: Pfizer Oncology Analyst Call Q&A Session
Pfizer Oncology Analyst Call Q&A Session June 9, 2017 22